Last reviewed · How we verify
Placebo lead in — Competitive Intelligence Brief
phase 3
Small molecule
Live · refreshed every 30 min
Target snapshot
Placebo lead in (Placebo lead in) — Technische Universität Dresden. Placebo lead-in is a study design phase where patients receive placebo before randomization to active treatment, used to establish baseline disease progression and identify placebo responders.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Placebo lead in TARGET | Placebo lead in | Technische Universität Dresden | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Placebo lead in CI watch — RSS
- Placebo lead in CI watch — Atom
- Placebo lead in CI watch — JSON
- Placebo lead in alone — RSS
Cite this brief
Drug Landscape (2026). Placebo lead in — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-lead-in. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab